Theralase Technologies's quarterly market cap
declined
from Sep. 2025 ($35.99 Mil) to Dec. 2025 ($31.31 Mil) but then
increased
from Dec. 2025 ($31.31 Mil) to Mar. 2026 ($54.95 Mil).
Theralase Technologies's annual market cap
increased
from Dec. 2023 ($31.07 Mil) to Dec. 2024 ($44.85 Mil) but then
declined
from Dec. 2024 ($44.85 Mil) to Dec. 2025 ($31.31 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Theralase Technologies's Enterprise Value for Today is $47.95 Mil.
Theralase Technologies (OTCPK:TLTFF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Market Cap distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Theralase Technologies's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a Market Cap of $48.35 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Theralase Technologies and its competitors. According to the industry distribution chart, Theralase Technologies ranks #544 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 62.8%.
Is Theralase Technologies' Market Cap too high?
Theralase Technologies' current Market Cap is $48.35 Mil. The Medical Devices & Instruments industry median Market Cap is 121.29. Theralase Technologies' value of $48.35 Mil is 60.1% below this industry median. Based on the distribution chart, Theralase Technologies ranks #544 out of 866 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #544 out of 866 companies for Market Cap. This places Theralase Technologies in the lower half of its industry. The industry median Market Cap is 121.29. Theralase Technologies' value of $48.35 Mil is 60.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.29, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current Market Cap of $48.35 Mil is 60.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current Market Cap is $48.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 28.1% above its estimated fair value. The current Market Cap is $48.35 Mil and 60.1% below the Medical Devices & Instruments industry median of 121.29. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Market Cap is $48.35 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.17 is trading 28.1% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Modestly Overvalued.
Key valuation signals for TLTFF:
Market Cap: $48.35 Mil
GF Value™: $0.13 vs. price of $0.17 (28.1% above fair value)
Industry Position: 60.1% below the Medical Devices & Instruments median (#544 of 866)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
